Core Viewpoint - The ChiNext Medical Index (970082) closed at 3876.07 points on February 3, with a gain of 2.37% and a trading volume of 13.236 billion yuan, indicating positive market sentiment in the medical sector [1]. Group 1: Index Performance - The ChiNext Medical Index saw 49 constituent stocks rise, with NuoSiGe leading the gains at 8.76% [1]. - The index's turnover rate was 1.71%, reflecting moderate trading activity [1]. Group 2: Top Constituents - The top ten constituents of the ChiNext Medical Index include: - YuanEr Eye Hospital (sz300015) with a weight of 9.18% and a latest price of 11.04 yuan, up 1.28% [1]. - MaiRui Medical (sz300760) with a weight of 8.95% and a latest price of 188.15 yuan, up 0.56% [1]. - TaiGe Medical (sz300347) with a weight of 8.52% and a latest price of 63.20 yuan, up 4.97% [1]. - KangLong HuaCheng (sz300759) with a weight of 7.18% and a latest price of 29.61 yuan, up 2.10% [1]. - LePu Medical (sz300003) with a weight of 4.96% and a latest price of 17.83 yuan, up 1.89% [1]. - New Industry (sz300832) with a weight of 4.73% and a latest price of 54.50 yuan, up 2.60% [1]. - AiMeiKe (sz300896) with a weight of 4.49% and a latest price of 147.57 yuan, up 4.56% [1]. - YingKe Medical (sz300677) with a weight of 4.14% and a latest price of 40.55 yuan, up 1.38% [1]. - FuRui Medical (sz300049) with a weight of 3.55% and a latest price of 67.33 yuan, up 1.45% [1]. - HuaDa Gene (sz300676) with a weight of 3.15% and a latest price of 50.30 yuan, up 2.57% [1]. Group 3: Capital Flow - The net inflow of main funds into the ChiNext Medical Index constituents totaled 145 million yuan, while retail investors experienced a net outflow of 106 million yuan [1]. - The detailed capital flow indicates that TaiGe Medical had a main fund net inflow of 10.514 million yuan, while retail investors had a net outflow of 18.28% [2].

Consumer Sector - Major companies are accelerating their C-end AI initiatives, with significant marketing investments exceeding 4.5 billion CNY from Tencent, ByteDance, and Baidu for the Spring Festival[4] - The top three AI applications have achieved over 100 million monthly active users (MAU): Doubao (approximately 320 million), Deepseek (approximately 150 million), and Qianwen (approximately 100 million) as of January 2026[7] High-end Manufacturing - Elon Musk announced plans to build 200 GW of solar capacity in the U.S. within three years, focusing on space-based solar energy, but the short-term impact on the photovoltaic industry remains limited[14] - Major photovoltaic companies are projected to incur significant losses in 2025, with Longi Green Energy, Tongwei Co., and TCL Zhonghuan each expected to lose over 6 billion CNY[17] Hard Technology - The electronic supply chain is experiencing a divergence in performance, with upstream companies like Western Digital and Seagate reporting better-than-expected earnings due to AI-driven demand, while downstream sectors face cost pressures[19] - Global smartphone SoC shipments are expected to decline by 7% in 2026, with low-end models under the most pressure[22] Health Sector - The CXO and research upstream sectors are showing signs of recovery, with notable profit growth expected for leading companies: WuXi AppTec's net profit is projected to increase by 102.65% to 19.15 billion CNY in 2025[26] - Global biopharmaceutical financing data is expected to show a 2.7% increase in 2025, with China's growth rate at 6.4%[28]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 杭州泰格醫藥科技股份有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 300347 | 說明 | | 於深圳證券交易所上市 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 737,901,250 | RMB | | | 1 RMB | | 737,901,250 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 737,901,250 | RMB | | | 1 RMB | | 737,901,250 | ...

Market Performance - The medical services sector increased by 2.52% on February 3, with Norsig leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up by 1.29%, while the Shenzhen Component Index closed at 14127.1, up by 2.19% [1] Top Gainers in Medical Services - Norsig (301333) closed at 78.98, up by 8.76% with a trading volume of 43,200 shares and a transaction value of 332 million [1] - Yinos (688710) closed at 61.07, up by 7.52% with a trading volume of 17,400 shares and a transaction value of 10.4 million [1] - Dean Diagnostics (300244) closed at 24.73, up by 6.69% with a trading volume of 447,200 shares and a transaction value of 1.084 billion [1] Market Capital Flow - The medical services sector saw a net inflow of 506 million from institutional investors, while retail investors experienced a net outflow of 4.12 billion [2][3] - The top stocks with significant institutional inflows included Tiger Medical (300347) with 103 million and Meinian Health (002044) with 86 million [3] Stock Performance Overview - The stock performance of various companies in the medical services sector showed a mix of gains and losses, with notable declines in stocks like Haocen Medical (002622) down by 1.97% [2] - The trading volume and transaction values varied significantly across different companies, indicating diverse investor interest [2]

致：香港交易及結算所有限公司 公司名稱: 杭州泰格醫藥科技股份有限公司 呈交日期: 2026年2月3日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 I. 法定/註冊股本變動 截至月份: 2026年1月31日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 300347 | 說明 | | 於深圳證券交易所上市 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 737,901,250 | RMB | | | 1 RMB | | 737,901,250 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 737,901,250 | RMB | | | 1 RMB | | 737,901,250 | ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [3] Core Insights - The comprehensive revision of the "Regulations on the Implementation of the Drug Administration Law" marks a significant shift towards innovation and regulatory upgrades in the pharmaceutical industry, effective from May 15, 2026 [6][32] - The new regulations emphasize innovation incentives and intellectual property protection, introducing market exclusivity periods for specific drug categories, which is expected to accelerate the approval process for new drugs [6][33] - The report highlights the potential for continued focus on the development of innovative drugs, particularly in the biopharmaceutical sector, as well as compliance and scaling of leading online pharmaceutical platforms and traditional Chinese medicine [6][36] Summary by Sections Market Review - The pharmaceutical and biotechnology index fell by 3.31% this week, underperforming the CSI 300 index by 3.39 percentage points, ranking 22nd in industry performance [11] - Year-to-date, the index has increased by 3.14%, outperforming the CSI 300 index by 1.49 percentage points [11] - The best-performing sub-sector this year is medical services, with an increase of 8.82%, while the chemical pharmaceuticals sub-sector has the smallest increase at 0.14% [16][19] Individual Stock Performance - In the A-share market, 59 out of 478 pharmaceutical and biotechnology stocks rose, with the top five performers being: - Cap Bio (+26.49%) - Hualan Biological (+12.8%) - Dezhan Health (+8.84%) - Wanzhou Co. (+7.94%) - Huakang Clean (+6.93%) [22] - In the Hong Kong market, 24 out of 116 stocks rose, with the top performers including: - Four Seasons Pharmaceutical (+17.91%) - Tigermed (+7.6%) - Weiya Biological (+6.22%) [25] Industry News and Policies - The State Council's revision of the drug administration regulations aims to enhance the regulatory framework, transitioning from risk control to a dual approach of lifecycle management and innovation incentives [32][33] - The new regulations include provisions for accelerated approval pathways for breakthrough therapies and special approvals, enhancing the regulatory environment for innovative drugs [33] - The report notes the introduction of a unified regulatory framework for online drug sales, ensuring compliance and traceability [33] Key Company Announcements - The report does not provide specific company announcements in this section [37]

泰格医药(03347)涨超4%，截至发稿，涨4.04%，报52.8港元，成交额2428.77万港元。 大摩发布研报称，泰格医药强劲的盈利增长主要归因于泰格医药资产的大幅重估，以及2024年相对较低 的基数。尽管受订单取消及收款困难影响，集团经常性收益表现疲软，但公司新订单增长依然强劲。扣 除取消订单后的新增在手订单净额介于95亿元至105亿元，同比增长13%至25%。大摩续指，集团管理 层对行业前景保持乐观，而近期的一次会议上，管理层提到中国CRO行业似乎正处于复苏态势。 智通财经APP获悉，泰格医药(03347)涨超4%，截至发稿，涨4.04%，报52.8港元，成交额2428.77万港 元。 消息面上，泰格医药近日发盈喜，高盛指出，公司预计2025年收入介乎66.6亿至76.8亿元人民币(下 同)，较该行及市场预期高。高盛表示，继续视公司为中国临床CRO行业结构性增长机遇的主要受惠 者，预期商业开发(BD)活动及融资环境自2025年起复苏，推动国内临床需求；跨国药企在中国的概念 验证(POC)临床试验潜在增加，提供进一步上行空间，显著的合约转化或自2026年上半年起开始显现。 ...

Group 1 - The major indices collectively rose on February 3, with the National Bio-Medical Index (399441) increasing by 1.15%. Notable stocks included Zhaoyan New Drug and Aimeike, both rising over 4%, while Tigermed and Huaxi Biological increased by over 3%, and Kailaiying rose nearly 3% [1] - The Bio-Medical ETF (159859) had a trading volume exceeding 65 million yuan, ranking first among its peers. The net inflow for this ETF on the previous trading day (February 2) was 67.29 million yuan, and it has seen continuous net inflows over the past 10 days, accumulating over 440 million yuan [1] - The latest circulating share of the Bio-Medical ETF is 9.569 billion shares, with a total market size of 3.674 billion yuan, making it the largest in its category [1] Group 2 - The Shanghai Municipal Government's work report emphasized the need to deepen the construction of an international economic center, focusing on modern industrial systems and supporting sectors such as bio-medicine, integrated circuits, and artificial intelligence [2] - According to Zhongtai Securities, the pharmaceutical market opportunities are expected to revolve around thematic opportunities, with potential performances in brain-computer interfaces, AI healthcare, and small nucleic acids. There is also a strategic emphasis on the raw material drug sector, which is at a bottom range and may see a mid-term positive cycle due to rising chemical prices and new business additions [2]

Core Insights - The healthcare sector in Hong Kong is experiencing significant growth opportunities driven by advancements in brain-computer interfaces, AI healthcare, and CXO services [2][18]. Group 1: Brain-Computer Interfaces - Neuralink, a company owned by Elon Musk, has commenced mass production, indicating a strong push in brain technology [2][18]. - Strong Brain Technology has completed a financing round of 2 billion yuan and is preparing for an IPO [2][18]. Group 2: AI Healthcare - Major AI companies are entering the healthcare space, with Alibaba launching "Ant Aifu" and OpenAI introducing ChatGPT Health [3][18]. Group 3: CXO Services - Companies such as WuXi AppTec, Tigermed, and Zhaoyan New Drug are forecasting net profits exceeding 100% for 2025, indicating positive performance expectations in the CXO sector [4][18]. Group 4: Market Performance - The healthcare index has shown high elasticity and volatility, with a maximum increase of 148.52% during the last pharmaceutical bull market, significantly outperforming comparable indices [8][22]. - The maximum decline since 2021 for the healthcare index was -80.73%, while the cumulative return since inception is -0.93% [10][24]. Group 5: Investment Opportunities - The Hong Kong Stock Connect Medical ETF provides a streamlined way to invest in leading healthcare companies in Hong Kong [20]. - The healthcare sector is characterized by high volatility, making it an attractive option for investors looking for significant returns [8][22].

Group 1 - The core viewpoint of the news is that the healthcare sector, particularly in A-shares and Hong Kong stocks, is experiencing significant activity and investment interest, driven by AI healthcare and CXO concepts [1][5][6] - The largest healthcare ETF in A-shares (512170) saw a net subscription of 2.633 billion yuan over the past 10 days, indicating strong investor interest [1][6] - The Hong Kong healthcare ETF (159137) rose by 2%, ending a three-day decline, with notable performances from stocks like Ark Health and BeiGene, which increased by over 20% and 4% respectively [1][4] Group 2 - Ark Health raised approximately 144 million HKD through a placement of about 45.181 million shares, with 90% of the funds allocated to accelerate the development of an AI-driven chronic disease management platform [3] - Huawei Cloud launched a dedicated "Smart Healthcare" section aimed at grassroots hospitals, providing AI pathology solutions, in collaboration with Ruijin Hospital [4] - By 2026, AI applications are expected to evolve from usable to highly effective, with a focus on diversified business models in sectors like healthcare, finance, and education [5]